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We have recently characterized a newneutrophil-activating peptide, called NAP-
2, whichis formed in platelet-containing cultures of stimulated human bloodmono-
nuclear cells (1). NAP-2 consists of 70 amino acids and has, therefore, about the
same size as NAF/NAP-1 (72 amino acids) (2). NAF/NAP-1 and NAP-2 are struc-
turally homologous and have similar effects on neutrophils (1). As shown in Fig.
1, NAP-2 corresponds to part of the sequence of platelet basicprotein (PBP) (3) and
connective tissue-activating peptide III (CTAP-III) (4), which is also known as low
affinity platelet factor 4 (3). It is structurally homologous to platelet factor 4 (PF4)
(5), another cx-granule protein and the murine inflammatory protein, MIP-2 (6).
We have compared theeffectsofNAF/NAP-1, NAP-2, and thea-granule peptides
on human neutrophils, and show here that NAP-2 behaveslike a typical chemotactic
receptor agonist inducing cytosolic free calcium changes, chemotaxis, and exocy-
tosis, while PBP, CTAP-III, and PF-4 have little if any such activity.
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Materials.
￿
Most ofthespecial reagents were describedpreviously (7). Fura-2/AM was ob-
tained from FlukaAG, Buchs, Switzerland; a-thrombin wasfrom Hoffmann-LaRocheLtd.,
Basel, Switzerland; and humanrecombinant NAF/NAP-1 wasfrom theSandoz Research In-
stitute, Vienna, Austria.
Cell Preparations.
￿
Human neutrophils were isolated and used as described previously (7).
Platelets were isolated from platelet-rich supernatants prepared from buffy coats (8). Suspen-
sions containing -10" platelets were washed three times in 0.15 M NaCl, 0.015 M sodium
citrate, 10 mM EDTA, pH 7.4, resuspended in 20 ml of the same buffer, warmed to 37°C,
and then stimulated for 10 min with 5 U/ml human a-thrombin. The reaction was stopped
by cooling to 4°C and the cell-free release supernatant wasobtained at 30,000 gfor 30 min
and used for peptide purification.
Peptides.
￿
Platelet releasesupernatant wasloaded at a flow rate of 25 ml/h onto a heparin-
sepharosecolumn (10 x 600mm) equilibrated in 50 mM Tris-HCI buffer, pH 7.4, containing
50 mM NaCl. After washingwith equilibration buffer, PBPandCTAP III were eluted with
a linear NaCl concentration gradient (0.05-1 M) in the same buffer. PF4 was eluted subse-
quentlywith 2 M NaCI. Fractions were tested for the presence of PBP, CTAP-III, and PF4
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by SDS-PAGE and further purified by reversed-phase HPLC on an analytical CN-propyl
column (4.6 x 250 mm, 5 Am, wide-pore; Baker Research Products, Phillipsburg, NJ) eluted
(0.5 ml/min) with a gradient of0-20% acetonitrile in 0.1% trifluoroacetic acid with an incre-
ment of 0.33% per minute. NAP-2 was purified as described (1). The purity was confirmed
by NH2-terminal sequencing of the first 12 residues.
BiologicalAssays.
￿
Neutrophil chemotaxis(9), cytosolic free calcium changes (7), and elastase
release (7) were determined according to established methods.
Results
Peptide Purification.
￿
PBP and CTAP-III were resolved from each other, and com-
pletely separated from PF4 by heparin-Sepharose chromatography (data not shown).
Upon reversed-phase HPLC, NAP-2, PBP, CTAP-III, and PF4 eluted with different
retention times (Fig. 2). Electrophoretically pure NAP-2, eluting as a single peak
from a C4-column (1), was recovered as a doublet from the CN-propyl column (Fig.
2), which was used to separate NAP-2 from the other species. HPLC-purified pep-
tides migrated as single bands in SDS-PAGE (not shown). They were identified by
NH2-terminal sequencing of the first 12 residues. A single sequence was obtained
for each species, indicating that they were indeed analytically pure.
The release supernatants of fresh thrombin-stimulated platelets contained PBP,
CTAP-III, and PF4, but no 0-thromboglobulin (OTG) or NAP-2 .
Elastase Release.
￿
Elastase release from cytochalasin B-pretreated neutrophils was
the biological assay used for NAF/NAP-1 (7) and NAP-2 (1). Both were now com-
pared with the peptides from the a-granules. As shown in Fig. 3 a, NAP-2 induced
significant release of elastase at concentrations between 0.3 and 100 nM, while only
minimal activity (N2% of that of NAP-2) was obtained with PBP at 100 nM, the
highest concentration used. CTAP-III, PF-4, and the lower concentrations of PBP
were inactive. NAP-2 was effective in the same molarity range as NAF/NAP-1, but
was about half as potent.
Cytosolic Free Calcium Changes.
￿
Stimulus-dependent fura-2 fluorescence changes
were recorded, and the rate offluorescence increase was determined. A similar, progres-
sive increase in the rate of the calcium rise was observed after stimulation with 0.1
to 100 nM NAP-2 and NAF/NAP-1 (Fig. 3 b). PBP, CTAP-III, and PF4 were virtu-
ally inactive up to a concentration of 10 nM, but showed some effect at 100 nM.
PBP was slightly more active than CTAP-III and PF4.
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FIGURE 1.
￿
Amino acid sequences of NAP-2 and related peptides aligned according to theirfour
cysteine residues. Residues common to all sequences are bold face. For NAP-2 and CTAP-III,
which are truncations of PBP, only a few NH2-terminal residues are indicated (top).E c
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Cfiemotaxis.
￿
As shown in Fig. 4a, NAP-2and NAF/NAP-1 induced concentration-
dependent chemotaxis between 0.03 and 1 nM. In this range, the two curves were
very similar in the six experiments performed. At higher concentrations, however,
NAFNAP-1 was consistently more active than NAP-2. PBP and CTAP-III had no
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FIGURE 2.
￿
Reversed-phase HPLC of purified
NAP-2, PBP, CTAP-III,andPF4on an analytical
CN-propylcolumn. Theretentiontimeswere 23.9
min for NAP-2, 36.0 min forPBP, 39.6 min for
CTAP-III, and 47.1 min for PF4.
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FIGURE 3.
￿
(a) Release of elastase from cytochalasin B-treated human neutrophils stimulated
with NAF/NAP-1 (A), NAP-2("), PBP (O), CTAP-III (-), andPF4(0). (b)Rate of thecyto-
solicfree calciumrise in humanneutrophils stimulated with NAF/NAP-1 (t1), NAP-2("), PBP
(O), CTAP-III (-), andPF4(0).(Inset) Single fura-2 fluorescence recordings in neutrophils stimu-
lated at time 0with 100, 10, 1, 0.1, and 0.01 nM NAP-2 (top to bottom). Similar results were
obtained in five (a)andthree(b) additional experiments performedwith differentcell preparations.1748
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FIGURE 4.
￿
Neutrophil chemotaxis inducedby (a)NAF/NAP-1 (A), NAP-2("), PBP(O), CTAP-
III (), and PF4 (0); (b) NAF/ NAP-1 (A), NAP-2 ("), and C5a (p). The highest effect, ob-
tained with 10 nM NAF/NAP-1, corresponded to the average migration of 41.2 t 8.6% of the
cell sample applied. Similar results were obtained in five (a) andtwo(b) additional experiments
performed with different cell preparations.
effect at 1 nM, and showed low levels of activity at 10 and 100 nM. PBP was again
slightly more active than CTAP-III. Fig. 4 b shows that NAP-2 and NAF/NAP-1
were equipotent with C5a, the most active naturally occurring chemotactic peptide
described so far.
Discussion
This study shows that NAP-2 is a powerful activator of human neutrophils, in-
ducing cytosolic free calcium changes, chemotaxis, and exocytosis at concentrations
between 0.3 and 10 nM, while its homologues, the platelet a-granule proteins PBP,
CTAP-III, and PF4, are practically inactive at concentrations up to 100 nM. NAP-2
is equipotent with NAF/NAP-1 and C5a as a stimulus for chemotaxis, but weaker
than these and other agonists as an inducer of exocytosis.
Of the platelet ct-granule proteins studied, PF4 was the first to be characterized
(5). It wasreported to be chemotactic forneutrophils, monocytes(10, 11), and fibroblasts
(12), and to induce neutrophil adherence and granule release (11). Except in the case
of fibroblasts (12), these responses were obtained at PF4 concentrations between
100 nM and -20 gM (11, 12), i.e., 100-10,000-fold higher than NAP-2, NAF/NAP-
1, and C5a in the present study. CTAP-III was reported to enhance mucopolysac-
charide synthesis and other metabolic processes in synovial cells (4, 13) and to be
mitogenic for fibroblasts (4), but notfor 3T3 cells(3). Such effects were notobtained
with the CTAP-III precursor PBP (3) and the CTAP-III cleavage product DWG (4).
None of these peptides were reported to activate neutrophils.
Ourobservation that PF4 is not chemotactic for neutrophils does not necessarily
contradict the earlier findings obtained at higher concentrations (10, 11). However,
in view ofthe high potency ofNAP-2, it must be realized that aminimal contamina-WALZ ET AL.
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tion with this peptidecould account forthe neutrophil-stimulating effects previously
attributed to PF4.
Platelets have long been thought to participate in intravascular inflammatory
processes through the release of vasoactive, proexudative, and phagocyte-activating
products (14). Neutrophils, which are often found in association with platelet ag-
gregates (15, 16), are presumably attracted by chemotactic mediators released as
a consequence of platelet activation. Up to now, platelet-activating factor was con-
sidered the most potent of theseattractants (17). The recent identification of NAP-2
as a powerful chemotactic fragment of PBP, however, suggests the existence of an
alternative mechanism of neutrophil recruitment that is related to ct-granule exocy-
tosis. Therecruitment ofneutrophils into platelet aggregates and thrombi via platelet-
derivedchemotaxinsmayconstitute amechanism forthedegradation ofthrombotic
deposits and the recanalization of obstructed vessels. On the other hand, activated
neutrophils could aggravate the course of thrombotic diseases and their sequelae,
as in atherosclerosis, by inducing inflammation and tissue damage.
Summary
Platelet basic protein (PBP), connective tissue-activating peptide III(CTAP-III),
and platelet factor 4 (PF4) were purified from human platelet release supernatants
by heparin-Sepharoseion-exchange andreversed-phase HPLC, and theirneutrophil-
activating effects were compared with those of NAP-2, a peptide of 70 amino acids
corresponding to part of the sequence of PBP (1) and with sequence homology to
NARNAP-1. NAP-2-induced elastase release and a rise in cytosolic free Ca2+ at
concentrations between 0.3 and 100 nM, and neutrophil chemotaxis at concentra-
tions between 0.03 and 10 nM. It was half as potent as NAF/NAP-1 in inducing
exocytosis but showed the same activity in the other responses. By contrast, only
minimal if any effects were obtained with PBP, CTAP-III, and PF4 up to 100 nM.
NAP-2 thus appears to behave like a typical chemotacticreceptor agonist. It could
be generated from PBP and/or CTAP-III released from activated platelets and lead
to the accumulation of neutrophils in platelet aggregates.
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